Literature DB >> 1373754

Haemophilus influenzae lipopolysaccharide disrupts confluent monolayers of bovine brain endothelial cells via a serum-dependent cytotoxic pathway.

D Patrick1, J Betts, E A Frey, R Prameya, K Dorovini-Zis, B B Finlay.   

Abstract

An in vitro blood-brain barrier (BBB) model consisting of primary cultures of bovine brain microvascular endothelial cells was used to examine the effect of Haemophilus influenzae type b (Hib) on the BBB. Whole bacteria and purified lipopolysaccharide (LPS; greater than 10 ng/ml) caused marked cytotoxicity on the bovine brain endothelial cells. This effect could be completely blocked by polymyxin B. Similar cytotoxic effects were observed with a cultured bovine pulmonary endothelial cell line. Serum was essential for the LPS-mediated cytotoxic effect, and human, horse, bovine, or fetal calf serum all had similar effects. The serum factor was not a complement component. A monoclonal antibody against CD14, a receptor involved in mediating the effect of LPS in monocytes, completely blocked the cytotoxic effect in both brain and pulmonary endothelial cells. These results suggest that Hib LPS disrupts an in vitro BBB model via a serum- and CD14-dependent pathway and that LPS has cytotoxic effects on bovine endothelial cells without the involvement of monocytic cells, an effect that may be important in gram-negative meningitis and in endotoxic shock.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1373754     DOI: 10.1093/infdis/165.5.865

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  25 in total

Review 1.  Concepts and mechanisms: crossing host barriers.

Authors:  Kelly S Doran; Anirban Banerjee; Olivier Disson; Marc Lecuit
Journal:  Cold Spring Harb Perspect Med       Date:  2013-07-01       Impact factor: 6.915

2.  Systemic inflammation alters the inflammatory response in experimental lipopolysaccharide-induced meningitis.

Authors:  T O'Reilly; C Ostergaard; J Vaxelaire; O Zak
Journal:  Clin Exp Immunol       Date:  2007-01       Impact factor: 4.330

3.  Group A Streptococcus induces apoptosis in human epithelial cells.

Authors:  P J Tsai; Y S Lin; C F Kuo; H Y Lei; J J Wu
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

Review 4.  Roles of proinflammatory and anti-inflammatory cytokines in pathophysiology of bacterial meningitis and effect of adjunctive therapy.

Authors:  A M van Furth; J J Roord; R van Furth
Journal:  Infect Immun       Date:  1996-12       Impact factor: 3.441

5.  Endotoxin-mediated endothelial cell injury and activation: role of soluble CD14.

Authors:  M Arditi; J Zhou; R Dorio; G W Rong; S M Goyert; K S Kim
Journal:  Infect Immun       Date:  1993-08       Impact factor: 3.441

6.  Lipopolysaccharide activation of human endothelial and epithelial cells is mediated by lipopolysaccharide-binding protein and soluble CD14.

Authors:  J Pugin; C C Schürer-Maly; D Leturcq; A Moriarty; R J Ulevitch; P S Tobias
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-01       Impact factor: 11.205

Review 7.  The role of CD14 and lipopolysaccharide-binding protein (LBP) in the activation of different cell types by endotoxin.

Authors:  R R Schumann; E T Rietschel; H Loppnow
Journal:  Med Microbiol Immunol       Date:  1994-12       Impact factor: 3.402

8.  Listeria monocytogenes infects human endothelial cells by two distinct mechanisms.

Authors:  D A Drevets; R T Sawyer; T A Potter; P A Campbell
Journal:  Infect Immun       Date:  1995-11       Impact factor: 3.441

9.  Cytotoxicity for lung epithelial cells is a virulence-associated phenotype of Mycobacterium tuberculosis.

Authors:  K A McDonough; Y Kress
Journal:  Infect Immun       Date:  1995-12       Impact factor: 3.441

10.  Lipopolysaccharide (LPS)-binding protein and soluble CD14 function as accessory molecules for LPS-induced changes in endothelial barrier function, in vitro.

Authors:  S E Goldblum; T W Brann; X Ding; J Pugin; P S Tobias
Journal:  J Clin Invest       Date:  1994-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.